Cite
HARVARD Citation
Taskinen, M. et al. (2018). Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis. pp. 124-130. [Online].